Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

A Quality Ensuring Project With Focus On Patients With Cardiovascular Diseases As Well As Type 2 Diabetes.

This study has been completed.
Information provided by (Responsible Party):
Pfizer Identifier:
First received: December 20, 2006
Last updated: April 21, 2015
Last verified: April 2015
The overall objective is to increase the adherence to national guidelines for patients with established CVD and/or Type 2 diabetes by means of repeated post-graduate educational meetings and regular evaluation of the optimisation initiatives, demonstrated by improvement of goal attainment in general practice.

Condition Intervention
Heart Diseases
Diabetes Mellitus, Type 2
Behavioral: Patient adherence to national educational guidelines.

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Patient And Physician Alliance -Guideline Education Treatment Optimization

Resource links provided by NLM:

Further study details as provided by Pfizer:

Enrollment: 2776
Study Start Date: January 2007
Study Completion Date: September 2008
Primary Completion Date: September 2008 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
Not Specified
Behavioral: Patient adherence to national educational guidelines.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Primary care clinic patients

Inclusion Criteria:

  • Subjects had to meet all of the inclusion criteria to be eligible for enrollment into the study. The following subjects qualify for inclusion in the study:
  • Subjects for whom measurement of total cholesterol, low density lipoprotein (LDL) cholesterol, blood pressure (BP) and glycosylated hemoglobin (HbA1c) was planned independently of this observational study and for whom baseline values were or became available.
  • Subjects with known CVD diagnosed > or = 6 months before inclusion
  • Previous myocardial infarction
  • Ischemic heart disease (stable and unstable angina pectoris)
  • Ischemic apoplexy
  • Peripheral arterial disease
  • And/Or
  • Subjects with T2D diagnosed > or = 6 months before inclusion
  • At least 50% of the subjects had to have CVD as the primary diagnosis. It was allowed for a secondary diagnosis to be <6 months before inclusion.

Exclusion Criteria:

  • Subjects presenting with any of the following were not to be included in the study:
  • Life expectancy of < or = 2 years
  • Unable/unwilling to understand/follow instructions
  • Taking part in a clinical study involving an investigational drug
  • Followed by a specialist for their CVD and/or T2D at the time of inclusion in the study
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00415428

Sponsors and Collaborators
Study Director: Pfizer Call Center Pfizer
  More Information

Additional Information:
Responsible Party: Pfizer Identifier: NCT00415428     History of Changes
Other Study ID Numbers: A2581154 
Study First Received: December 20, 2006
Last Updated: April 21, 2015
Health Authority: Denmark: Danish Medicines Agency

Additional relevant MeSH terms:
Diabetes Mellitus
Heart Diseases
Diabetes Mellitus, Type 2
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Cardiovascular Diseases processed this record on October 21, 2016